摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氨基-3-苯甲酰基-2-甲基吡咯 | 57436-07-4

中文名称
4-氨基-3-苯甲酰基-2-甲基吡咯
中文别名
——
英文名称
2-methyl-3-benzoyl-4-aminopyrrole
英文别名
(4-amino-2-methyl-pyrrol-3-yl)-phenyl-methanone;4-amino-3-benzoyl-2-methylpyrrole;Methanone, (4-amino-2-methyl-1H-pyrrol-3-yl)phenyl-;(4-amino-2-methyl-1H-pyrrol-3-yl)-phenylmethanone
4-氨基-3-苯甲酰基-2-甲基吡咯化学式
CAS
57436-07-4
化学式
C12H12N2O
mdl
——
分子量
200.24
InChiKey
APPNFPAQYIBGLU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    405.0±45.0 °C(Predicted)
  • 密度:
    1.217±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    58.9
  • 氢给体数:
    2
  • 氢受体数:
    2

SDS

SDS:7ce14d7086b378b9327c9cf1f267cf82
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • PYRROLO- AND PYRAZOLO-TRIAZOLODIAZEPINES AS BET-PROTEIN INHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20160009725A1
    公开(公告)日:2016-01-14
    What is described are BET protein-inhibitory, especially BRD2-, BRD3- and BRD4-inhibitory, bicyclo- and spino-substituted pyrrolo- and pyrazolodiazepines of the general formula I in which X, Y, n, m, R 1 , R 2 , R 3 , R 4 and R 5 are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for tumour disorders. Also described is the use of the compounds according to the invention as BET protein inhibitors for benign hyperplasias, for atherosclerotic disorders, for sepsis, for autoimmune disorders, for vascular disorders, for viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for male fertility control.
    所描述的是BET蛋白抑制剂,特别是BRD2、BRD3和BRD4抑制剂,其为通式I的双环和螺环取代的吡咯烷和吡唑二氮杂环化合物,其中X、Y、n、m、R1、R2、R3、R4和R5如描述中所定义,以及用于制备本发明化合物的中间体,包含本发明化合物的制药组合物,以及其预防和治疗肿瘤性疾病等增生性疾病的用途。还描述了本发明化合物作为BET蛋白抑制剂用于良性增生、动脉硬化性疾病、败血症、自身免疫性疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉硬化性疾病和男性生育控制的用途。
  • 4-SUBSTITUTED PYRROLO- AND PYRAZOLO-DIAZEPINES
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20150376196A1
    公开(公告)日:2015-12-31
    BET protein-inhibitory, especially BRD2-, BRD3- and BRD4-inhibitory, 4-substituted pyrrolo- and pyrazolodiazepines of the general formula I are described, in which X, Y, n, m, p, R 1 , R 2 , R 3 , R 4 and R 5 are each as defined in the description, as are pharmaceutical compositions comprising the inventive compounds, and the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of neoplastic disorders. Also described is the use of the inventive compounds as BET protein inhibitors in benign hyperplasias, in atherosclerotic disorders, in sepsis, in autoimmune disorders, in vascular disorders, in viral infections, in neurodegenerative disorders, in inflammatory disorders and in male fertility control.
    本发明涉及BET蛋白抑制剂,特别是BRD2、BRD3和BRD4抑制剂,以及一般式I的4-取代吡咯烷和吡唑烷二氮杂环化合物,其中X、Y、n、m、p、R1、R2、R3、R4和R5如描述中所定义,以及包含这些化合物的药物组合物,以及在高增殖性疾病,特别是恶性肿瘤疾病的预防和治疗中的预防和治疗用途。本发明还描述了这些创新化合物作为BET蛋白抑制剂在良性增生、动脉粥样硬化性疾病、败血症、自身免疫性疾病、血管障碍、病毒感染、神经退行性疾病、炎症性疾病和男性生育控制中的应用。
  • 1,7-Dihydro-pyrrolo[3,4-e][1,4]diazepin-2(1H)-one derivatives
    申请人:Gruppo Lepetit S.p.A.
    公开号:US04402970A1
    公开(公告)日:1983-09-06
    1,7-Dihydro-pyrrolo[3,4-e][1,4]diazepin-2(1H)-ones of the formula ##STR1## wherein R is lower alkyl, R.sub.1 stands for hydrogen, methyl, ethyl or phenyl, R.sub.2 is hydrogen or lower alkyl and R.sub.3 is hydrogen, chloro, fluoro, bromo, trifluoromethyl or methoxy are described with anticonvulsant and anti-anxiety activity. Also described is the process for preparing the above compounds and pharmaceutical preparations containing them.
    本文描述了公式为##STR1##的1,7-二氢-吡咯并[3,4-e][1,4]二氮杂环己酮,其中R表示低碳基,R.sub.1表示氢、甲基、乙基或苯基,R.sub.2为氢或低碳基,R.sub.3为氢、氯、氟、溴、三氟甲基或甲氧基,并具有抗惊厥和抗焦虑活性。还描述了制备上述化合物的过程以及含有它们的制药制剂。
  • Pharmacologically active pyrrolodiazepines
    申请人:Gruppo Lepetit S.p.A.
    公开号:US04022766A1
    公开(公告)日:1977-05-10
    Compounds of the following formula ##STR1## wherein R is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl or tert.-butyl; R.sub.1 is hydrogen, methyl, ethyl or phenyl; R.sub.2 is hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl or tert.-butyl; R.sub.3 is hydrogen, methoxy, trifluoromethyl, chloro, bromo or fluoro; and R.sub.4 is methyl. The new compounds are useful as CNS depressants, anticonvulsants, anti-inflammatories and inhibitors of the enzymes which promote the synthesis of prostaglandins.
    以下化合物的化学式为 ##STR1## 其中R为氢,甲基,乙基,丙基,异丙基,丁基,异丁基,仲丁基或叔丁基;R.sub.1为氢,甲基,乙基或苯基;R.sub.2为氢,甲基,乙基,丙基,异丙基,丁基,异丁基,仲丁基或叔丁基;R.sub.3为氢,甲氧基,三氟甲基,氯,溴或氟;R.sub.4为甲基。这些新化合物可用作中枢神经系统抑制剂,抗惊厥剂,抗炎剂和促进前列腺素合成的酶的抑制剂。
  • 1,7-Dihydro-pyrrolo(3,4-e)(1,4)diazepin-2(1H)-one derivatives
    申请人:GRUPPO LEPETIT S.P.A.
    公开号:EP0066762A2
    公开(公告)日:1982-12-15
    1,7-Dihydro-pyrrolo[3,4-e][1,4]diazepin-2(1H)-ones of the formula wherein R is lower alkyl, R, stands for hydrogen, methyl, ethyl or phenyl, R2 is hydrogen or lower alkyl and R3 is hydrogen, chloro, fluoro, bromo, trifluoromethyl or methoxy are described with anticonvulsant and anti-anxiety activity. Also described is the process for preparing the above compounds and pharmaceutical preparations containing them.
    式中的 1,7-二氢-吡咯并[3,4-e][1,4]二氮杂卓-2(1H)-酮 其中 R 是低级烷基,R 代表氢、甲基、乙基或苯基,R2 是氢或低级烷基,R3 是氢、氯、氟、溴、三氟甲基或甲氧基。 还描述了上述化合物的制备过程和含有这些化合物的药物制剂。
查看更多